Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8237155 | International Journal of Radiation Oncology*Biology*Physics | 2008 | 6 Pages |
Abstract
Gefitinib can be associated with 5-FU-based preoperative chemoradiation at the dose of 500 mg without any life-threatening toxicity and with a high pCR (30.3%). The relevant rate of Grade 3 gastrointestinal toxicity suggests that 250 mg would be more tolerable dose in a neaoadjuvant approach with radiotherapy and infusional 5-FU.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Vincenzo M.D., Antonino M.D., Maria Antonietta M.D., Giovanna M.D., Carlo M.D., Fabio Maria M.D., Brunella M.D., Roberto M.D., Carlo M.D., Giovanni M.D., Maria Cristina M.D., Alessandro M.D., Marco M.D., Giovan Battista M.D.,